ORLANDO, Fla., Nov. 5, 2015 /PRNewswire/ -- iRhythm Technologies, Inc. announced today that Dr. Uday N. Kumar, founder of the company, will deliver two presentations during the American Heart Association (AHA) Scientific Sessions on November 9, 2015:
"While digital health technology is starting and will continue to transform the way healthcare is delivered, ultimately the most important technologies will be the ones that show true value in the delivery of health care," said Kumar, who is also a cardiac electrophysiologist and Consulting Associate Professor of Bioengineering at Stanford University. "Specifically, the digital and mobile health technologies that are based on truly solving an unmet need, and can provide data that they actually do add clinical and economic value, will lead to better clinical understanding and improved, more cost-effective management of cardiac conditions such as arrhythmias. These innovations may result in quicker diagnosis and treatment, improved patient experiences and outcomes and lower health care costs."
Each year, tens of millions of patients see physicians because they experience symptoms that may be caused by an irregular heartbeat. However, arrhythmias are difficult to diagnose since they are often sporadic. If left undiagnosed and untreated, arrhythmias can significantly increase the risk of stroke and other health complications.
iRhythm Technologies' ZIO® Service enables improved arrhythmia detection by integrating easily wearable biosensor technology that continuously records electrocardiography data for up to 14 days with a powerful analytics and reporting engine. Since its U.S. Food and Drug Administration clearance and commercial launch, more than 90 million hours of data has been collected, analyzed, and reported for nearly 400,000 patients in the U.S.
"Traditional cardiac monitoring solutions such as Holter and Event monitors are limited in their ability to detect cardiac arrhythmias because they do not capture enough, or the most relevant, information," said Judy Lenane, RN, MHA, Executive Vice President and Chief Clinical Officer of iRhythm Technologies, Inc. "The ZIO Service records and stores beat-to-beat data in its entirety, which can provide a more complete picture to a healthcare provider and allow for a more accurate diagnosis with one test. The single-use ZIO Patch is also a wearable technology that is very discreet, so patients prefer it."
Various studies have shown that the ZIO Service wearable biosensor (ZIO Patch) and powerful cloud-based analytics provide great clinical value for an outpatient population. Studies indicate that ZIO provides a patient-preferred1 method of ambulatory monitoring compared to Holter monitoring with the added benefit that many arrhythmias are detected past the 48-hour wear limit for traditional Holters.2,3 The use of ZIO has been shown to increase the ability to reach a definitive diagnosis1 and also resulted in changed clinical management for about a third of the patients studied.4 In a recent study of high-risk but asymptomatic patients, the ZIO Service detected atrial fibrillation and atrial tachycardia in 11 percent of the group.5 Early detection of these arrhythmias may prevent strokes and heart failure.
About iRhythm Technologies, Inc.
iRhythm is a privately held digital healthcare solutions company that is a world leader in cardiac arrhythmia information. The company is combining wearable biosensor devices with mobile and cloud-based technology to improve how heart arrhythmias are diagnosed and managed. iRhythm's digital health technology and diagnostic support services provide clear, actionable information for physicians, and are clinically proven to enhance clinical decision making and lower healthcare costs. Its flagship solution, the ZIO Service, offers a proven approach to long-term continuous monitoring that enables diagnosis earlier in the clinical pathway to improve patient outcomes and reduce healthcare costs. For more information, please visit www.irhythmtech.com.
|
1 |
Barrett, P., Komatireddy, R., Haaser, S. et al. Comparison of 24 Hour Holter Monitoring Versus 14 Day Novel Adhesive Patch Electrocardiographic Monitoring. American Journal of Medicine. 2014;127: 95.e11-95.e17. |
|
2 |
Turakhia M., Hoang D., Zimetbaum P. et al. Diagnostic Utility of a Novel Leadless Arrhythmia Monitoring Device. The American Journal of Cardiology. 2013;112(4): 520-524. |
|
3 |
Eisenberg, Evanne., MD, Carlson, Steven K., MD, Saxon, Leslie A., MD et al. Chronic Ambulatory Monitoring: Results of a Large Single-Center Experience. The Journal of Innovations in Cardiac Rhythm Management. 5 (2014), 1818-1823. |
|
4 |
Rosenberg MA, Samuel M, Thosani A, Zimetbaum PJ. Use of a Noninvasive Continuous Monitoring Device in the Management of Atrial Fibrillation: a Pilot Study. Pacing Clin Electrophysiol. 2013;36: 328-333. |
|
5 |
Turakhia MP, Ullal AJ, Hoang DD, Than CT, Miller JD, Friday KJ, Perez MV, Freeman JV, Wang PJ, and Heidenreich PA. Feasibility of Extended Ambulatory Electrocardiogram Monitoring to Identify Silent Atrial Fibrillation in High-Risk Patients: The Screening Study for Undiagnosed Atrial Fibrillation (STUDY-AF). Clinical Cardiology Journal. 14 APR 2015 | DOI: 10.1002/clc.22387. |
Media Contact
Amanda Breeding
Amanda.breeding@edelman.com
415-229-7649
SOURCE iRhythm Technologies, Inc.